Main Industry
Health Care
Main Product/Service
1. ASP5006
2. ASP4755
2. ASP4755
The content above was translated by Ai
Founded Year
2011
Unified Business No.
53203779
Status
Closed
Number of Employees
8
Total Paid-in
Capital
151,400,000 (NT$)
Location of Company
Taiwan
, Hsinchu County
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Asclepiumm Taiwan Co., Ltd. was established in 2011 and is a pioneering pharmaceutical development company focused on addressing unmet medical needs in the market. The company specializes in the research and development of innovative first-in-class drugs utilizing the ASC fusion protein platform and unique peptide drug development. In 2016, Asclepiumm established three major research axes: peptides, antibodies, and fusion proteins.
As of 2023, the company has developed two series of peptide drugs, an antibody platform, and a fusion protein drug platform, all of which have been granted patents in the United States, China, and Japan. These research achievements will be further developed through collaborations with professional Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) in the subsequent phases of drug development.
The products under development are characterized by their novelty, addressing urgent medical needs, and the potential to become blockbuster drugs with annual sales exceeding 1 billion USD. There are opportunities for early-stage licensing and collaboration with international pharmaceutical giants, which can accelerate and enhance the success of new drug development and contribute to the expansion of future markets.
As of 2023, the company has developed two series of peptide drugs, an antibody platform, and a fusion protein drug platform, all of which have been granted patents in the United States, China, and Japan. These research achievements will be further developed through collaborations with professional Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) in the subsequent phases of drug development.
The products under development are characterized by their novelty, addressing urgent medical needs, and the potential to become blockbuster drugs with annual sales exceeding 1 billion USD. There are opportunities for early-stage licensing and collaboration with international pharmaceutical giants, which can accelerate and enhance the success of new drug development and contribute to the expansion of future markets.
The content above was translated by Ai
